• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mott David M bought $388,738 worth of shares (77,729 units at $5.00), increasing direct ownership by 4% to 2,015,494 units (SEC Form 4)

    2/26/25 7:21:25 PM ET
    $ARDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARDX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MOTT DAVID M

    (Last) (First) (Middle)
    C/O ARDELYX, INC.
    400 FIFTH AVENUE, SUITE 210

    (Street)
    WALTHAM MA 02451

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ARDELYX, INC. [ ARDX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/24/2025 P 77,729(1) A $5.0012 2,015,494(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Transaction was executed in multiple trades in prices ranging from $4.90 to $5.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
    2. The Reporting Person holds 87,566 shares for the benefit of entities associated with New Enterprise Associates and disclaims beneficial ownership of such shares, except to the extent of his actual pecuniary interest therein.
    Remarks:
    /s/ Elizabeth Grammer, Attorney-in-Fact for David Mott 02/26/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ARDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDX

    DatePrice TargetRatingAnalyst
    5/2/2025$11.00Strong Buy → Outperform
    Raymond James
    3/7/2025Buy
    Ladenburg Thalmann
    3/4/2025$14.00Buy
    BTIG Research
    11/11/2024$11.00 → $5.50Buy → Neutral
    H.C. Wainwright
    7/2/2024$15.00 → $7.00Overweight → Neutral
    Piper Sandler
    4/5/2024$14.00Outperform
    Leerink Partners
    12/18/2023$12.00Strong Buy
    Raymond James
    9/7/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $ARDX
    SEC Filings

    See more
    • SEC Form 144 filed by Ardelyx Inc.

      144 - ARDELYX, INC. (0001437402) (Subject)

      5/2/25 4:22:02 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ardelyx Inc.

      10-Q - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:04:48 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARDELYX, INC. (0001437402) (Filer)

      5/1/25 4:03:36 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      11/14/24 4:08:33 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ardelyx Inc.

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      7/10/24 6:32:11 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ardelyx Inc. (Amendment)

      SC 13G/A - ARDELYX, INC. (0001437402) (Subject)

      2/13/24 5:26:59 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael sold $177,168 worth of shares (41,666 units at $4.25) and exercised 20,833 shares at a strike of $0.99, decreasing direct ownership by 1% to 1,594,754 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:14:10 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Raab Michael exercised 20,833 shares at a strike of $0.99 and sold $191,151 worth of shares (41,666 units at $4.59), decreasing direct ownership by 1% to 1,615,587 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      4/8/25 7:24:24 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      10/20/23 4:37:52 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZAH issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:43:04 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for XPHOZA™ issued to ARDELYX INC

      Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling

      10/18/23 4:37:08 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Financials

    Live finance-specific insights

    See more
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

      WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 1, 2025, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2025. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves

      4/17/25 8:00:56 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Company achieved significant commercial progress in 2024, finishing with total revenue of $333.6 million, including $319.2 million in U.S. Net Product Sales Company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended

      2/20/25 7:30:54 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

      WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company presented data supporting the company's first-in-class retainagogue, IBSRELA® (tenapanor), as well as results from the IBS in America 2024 supplemental survey, at the Digestive Disease Week Conference (DDW), now underway in San Diego. IBSRELA is approved by the U.S. Food and Drug Administration to treat irritable bowel syndrome with constipation (IBS-C) in adults. "Ardelyx is committed to continuing to grow

      5/6/25 8:01:45 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

      Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million  Company ends Q1 with $214.0 million in cash, cash equivalents and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2025 and provided a business update. "Ardelyx deliver

      5/1/25 4:01:51 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ardelyx downgraded by Raymond James with a new price target

      Raymond James downgraded Ardelyx from Strong Buy to Outperform and set a new price target of $11.00

      5/2/25 8:06:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Ardelyx

      Ladenburg Thalmann resumed coverage of Ardelyx with a rating of Buy

      3/7/25 8:02:22 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Ardelyx with a new price target

      BTIG Research initiated coverage of Ardelyx with a rating of Buy and set a new price target of $14.00

      3/4/25 7:19:29 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mott David M bought $1,610,936 worth of shares (381,377 units at $4.22), increasing direct ownership by 19% to 2,396,871 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      5/5/25 8:22:23 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $388,738 worth of shares (77,729 units at $5.00), increasing direct ownership by 4% to 2,015,494 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      2/26/25 7:21:25 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mott David M bought $992,672 worth of shares (199,000 units at $4.99), increasing direct ownership by 11% to 1,937,765 units (SEC Form 4)

      4 - ARDELYX, INC. (0001437402) (Issuer)

      1/22/25 5:25:52 PM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

      WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Merdad Parsey, M.D., Ph.D. to the company's board of directors. "We are thrilled to welcome Merdad to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "Merdad is a veteran biotech leader and clinician with a commitment to patients that aligns with the Ardelyx vision of a healthier tomorrow for patients. His broad leadership experience spans the entire pharmaceutical d

      4/29/25 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer

      WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te

      8/8/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

      WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.

      3/25/24 8:00:00 AM ET
      $ARDX
      Biotechnology: Pharmaceutical Preparations
      Health Care